Cofrogliptin vs Gemigliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Cofrogliptin
Marketed by Haisco Pharmaceutical Group
NCT04556851 · Phase 3 · completed
This randomized, double-blind, placebo-controlled trial enrolled 476 patients and measured change in HbA1c, a standard efficacy measure in diabetes, at 24 weeks. Both HSK7653 doses lowered HbA1c significantly more than placebo (p<0.0001), meeting the trial's primary goal.
Next expected readout: June 2027 · NCT07122102 (registry estimate)
Reported efficacy
HbA1c Change From Baseline at Week 24 (Baseline and week 24): HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin (met)
Result source: NCT04564872
Gemigliptin · Zemiglo
Marketed by LG Chem and partners
NCT01787396 · Phase 3 · completed
This was a randomized, quadruple-blind trial (n=433) with three arms: gemigliptin plus metformin, gemigliptin alone (with a matching metformin placebo), and metformin alone (with a matching gemigliptin placebo). The primary endpoint, HbA1c change at 24 weeks, favored the combination over either monotherapy.
Reported efficacy
Changes from baseline HbA1c at week 24 (Baseline (week 0) and week 24): LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%. (met)
Result source: NCT03842267
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cofrogliptin | Gemigliptin |
|---|---|---|
| HbA1c, change | -1.0% vs -1.1%avs linagliptin 5 mgNCT045648721 other result
| -0.8% vs 0.4%a−1.2 vs placeboNCT019680442 other results
|
| Body weight, change (kg) | —Not posted · NCT04564872 | —Not posted · NCT01787396 |
| HbA1c below 7% | —Not posted · NCT04564872 | —Not posted · NCT01787396 |
| Fasting plasma glucose, change | —Not posted · NCT04564872 | —Not posted · NCT01787396 |
| 3-point MACE (% with event) | —Not posted · NCT04564872 | —Not posted · NCT01787396 |
HbA1c, change
- Cofrogliptin
- -1.0% vs -1.1%avs linagliptin 5 mgNCT04564872
1 other result
- -1.0% vs -1.1% NCT04564872
- Gemigliptin
- -0.8% vs 0.4%a−1.2 vs placeboNCT01968044
2 other results
- -2.1% vs -1.5% NCT01787396
- -1.2% vs -1.5% NCT01787396
Body weight, change (kg)
- Cofrogliptin
- —Not posted · NCT04564872
- Gemigliptin
- —Not posted · NCT01787396
HbA1c below 7%
- Cofrogliptin
- —Not posted · NCT04564872
- Gemigliptin
- —Not posted · NCT01787396
Fasting plasma glucose, change
- Cofrogliptin
- —Not posted · NCT04564872
- Gemigliptin
- —Not posted · NCT01787396
3-point MACE (% with event)
- Cofrogliptin
- —Not posted · NCT04564872
- Gemigliptin
- —Not posted · NCT01787396
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint
Coverage. Cofrogliptin: 1 of 1 rows · Gemigliptin: 1 of 1 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cofrogliptin Rows use multiple source trials | Gemigliptin Rows use multiple source trials |
|---|---|---|
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.59% @ 24wk25 mga,b,c NCT04556851 · Phase 3 · sponsor-reported, not registry data show 1 more dose-0.63% @ 24wkcofrogliptin (HSK7653) 10 mg NCT04556851 · Phase 3 · sponsor-reported, not registry data | -0.7% @ 24wkgemigliptin 50 mgb,c NCT02831361 · Phase 3 · sponsor-reported, not registry data 1 other source trial-0.66% @ 24wk NCT03842267 · Phase 3 · sponsor-reported, not registry data |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cofrogliptin's landscape · Gemigliptin's landscape